See also this year's filing and all EDGAR filings for this company.
PDF Report 0001606645_2019_Foamix_Pharmaceuticals_Ltd.pdf
Logs
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Assets', 'missing_ratio': 0.02412154852062656, 'aggregate_val': 103731000, 'exp_sum': 106295000, 'exp_to_value': {'AssetsCurrent': 101167000, 'AssetsNoncurrent': 2564000, 'PropertyPlantAndEquipmentNet': 2235000, 'Goodwill': 0, 'remainder_Assets': 329000}} |
| info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('EntityCommonStockSharesOutstanding')"} |
Graph
Absolute values for 0001606645, Foamix Pharmaceuticals Ltd.
| xvar | xval | |
|---|---|---|
| 0 | LiabilitiesNoncurrent | 1,081,000 |
| 1 | LiabilitiesCurrent | 10,468,000 |
| 2 | remainder_Liabilities | 0 |
| 3 | AssetsCurrent | 101,167,000 |
| 4 | AssetsNoncurrent | 2,564,000 |
| 5 | PropertyPlantAndEquipmentNet | 2,235,000 |
| 6 | Goodwill | 0 |
| 7 | remainder_Assets | -2,235,000 |
| 8 | GeneralAndAdministrativeExpense | 14,013,000 |
| 9 | ResearchAndDevelopmentExpense | 64,474,000 |
| 10 | remainder_Expenses | 212,000 |
| 11 | remainder_Revenues | 3,595,000 |
| 12 | remainder_NetIncome | 941,000 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Liabilities | 11,549,000 |
| 1 | Assets | 103,731,000 |
| 2 | Expenses | 78,699,000 |
| 3 | Revenues | 3,595,000 |
| 4 | StockholdersEquity | 92,182,000 |
| 5 | NetIncome | -74,163,000 |
| 6 | ComprehensiveNetIncome | -74,163,000 |
| 7 | BaseVar | 99,257,500 |
| 8 | EconomicCapitalRatio | 0.0727 |
Edgar->Model Mapping
Feature Distribution
Change over Time
